On Friday, Bausch Health Companies Inc. (NYSE:BHC) experienced a downgrade in its stock rating by Piper Sandler from Neutral to Underweight. The firm also reduced the price target for the company's shares significantly, setting it at $3.00, a steep decline from the previous target of $9.00.
The downgrade was prompted by concerns surrounding Bausch Health's considerable debt obligations and the impending loss of exclusivity for its key drug, Xifaxan.
The debt, amounting to approximately $9.4 billion, is set to mature around 2027/2028. This financial pressure is compounded by the fact that Xifaxan is expected to lose its exclusivity by January 2028 at the latest, which could impact the company's revenue streams.
Piper Sandler highlighted the company's net debt to LTM EBITDA ratio for the Pharma business, which stands at around 6.5 times, indicating a significant leverage level.
The firm suggests that despite management's efforts to shift focus, such as the development of a next-generation rifaximin formulation (RED-C), concerns about the company's solvency will persist due to these looming challenges.
The downgrade comes even as Bausch Health reported second-quarter earnings for 2024 that were largely in line with expectations. The company posted a diluted non-GAAP EPS of $0.89 on revenue of $2.4 billion, which was on par with consensus estimates of $0.88 in EPS and $2.3 billion in revenue. Moreover, Bausch Health reiterated its 2024 revenue and adjusted EBITDA guidance ranges for the Pharma business.
Piper Sandler's position reflects a view that the company's current financial state and upcoming challenges overshadow the recent performance and projections.
The lower price target and rating downgrade are reactions to the anticipated impact of debt maturity and drug exclusivity expiration on Bausch Health's financial health.
In other recent news, Bausch Health Companies Inc. has been the subject of several noteworthy developments. The company reported a Q2 revenue of $1.19 billion, marking a 5% increase on a reported basis and a 6% increase organically.
Notably, Bausch Health's Xifaxan product saw a 10% revenue growth, contributing to the Salix segment's revenue increase to $558 million. However, the company faces upcoming generic competition for Xifaxan, which could impact future revenue streams.
Furthermore, Bausch Health was downgraded by Piper Sandler from Neutral to Underweight due to concerns over its considerable debt obligations and the impending loss of exclusivity for Xifaxan. The firm also reduced the price target for the company's shares to $3.00, a significant decline from the previous target of $9.00.
Despite these challenges, Bausch Health maintains its full-year guidance with expected revenue between $4.7 billion and $4.85 billion and adjusted EBITDA from $2.36 billion to $2.46 billion.
The company remains committed to driving growth and maintaining operational effectiveness, with a focus on balance sheet strength, liquidity, and the potential full separation of Bausch + Lomb.
InvestingPro Insights
Amid the concerns highlighted by Piper Sandler, real-time data from InvestingPro offers a snapshot of Bausch Health Companies Inc.'s (NYSE:BHC) financial state. With a market capitalization of $2.2 billion, the company's valuation reflects a complex picture. The adjusted P/E ratio for the last twelve months as of Q1 2024 stands at a high 80.12, suggesting investors may be expecting future earnings growth to justify the current stock price. This aligns with one of the InvestingPro Tips that net income is expected to grow this year. Additionally, the company's revenue growth over the last twelve months was a solid 10.01%, and the gross profit margin was a robust 70.81%, indicating a strong ability to convert sales into profit.
However, the InvestingPro Tips also point out that Bausch Health has not been profitable over the last twelve months, which may be a cause for concern for potential investors. Analysts predict the company will be profitable this year, which could provide some optimism amidst the downgrade. Furthermore, Bausch Health's management has been aggressively buying back shares, a move that can signal confidence in the company's future prospects and potentially support the stock price.
For those interested in a deeper analysis, InvestingPro offers additional insights and tips on Bausch Health, which may be particularly useful for investors considering the company's future amid its current challenges. There are several more InvestingPro Tips available, providing a comprehensive understanding of Bausch Health's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.